Scleroderma: from cell and molecular mechanisms to disease models, Trends Immunol, vol.26, pp.587-95, 2005. ,
Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatol Oxf Engl, vol.51, pp.1017-1043, 2012. ,
Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities, J Scleroderma Relat Disord, vol.2, pp.137-52, 2017. ,
Transforming growth factor beta as a therapeutic target in systemic sclerosis, Nat Rev Rheumatol, vol.5, pp.200-206, 2009. ,
The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol, vol.11, pp.191-212, 1993. ,
New perspectives of CD28-B7-mediated T cell costimulation, Immunity, vol.2, pp.555-564, 1995. ,
T-cell co-stimulatory pathways in autoimmunity, Arthritis Res Ther, vol.10, 2008. ,
The B7-CD28 superfamily, Nat Rev Immunol, vol.2, pp.116-142, 2002. ,
Costimulatory pathways in transplantation, Semin Immunol, vol.23, pp.293-303, 2011. ,
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, vol.3, pp.90125-90131, 1995. ,
Molecular mechanisms of T cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy, Immunol Rev, vol.229, pp.337-55, 2009. ,
Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis, Clin Exp Immunol, vol.136, pp.388-92, 2004. ,
Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis, Ann Rheum Dis, vol.69, pp.550-555, 2010. ,
Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis, Rheumatol Oxf Engl, vol.43, pp.1261-1267, 2004. ,
Targeting T cell costimulation in autoimmune disease, Expert Opin Ther Targets, vol.6, pp.275-89, 2002. ,
Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations, Immunol Lett, vol.198, pp.12-18, 2018. ,
ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis, Cytom Part J Int Soc Anal Cytol, vol.71, pp.317-343, 2007. ,
Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus, Arthritis Rheum, vol.50, pp.3211-3231, 2004. ,
Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS, Blood, vol.96, pp.2808-2821, 2000. ,
Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis, Arch Dermatol Res, vol.305, pp.17-23, 2013. ,
Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis, Rheumatol Oxf Engl, vol.52, pp.242-51, 2013. ,
Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells, J Immunol Baltim Md, vol.1950, pp.2108-2123, 2001. ,
Outside inside signalling in CD40-mediated B cell activation, J Biol Regul Homeost Agents, vol.21, pp.49-62, 2007. ,
Increased serum soluble OX40 in patients with systemic sclerosis, J Rheumatol, vol.35, pp.2359-62, 2008. ,
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort, Ann Rheum Dis, vol.70, pp.638-679, 2011. ,
OX40L blockade protects against inflammation-driven fibrosis, Proc Natl Acad Sci, vol.113, pp.3901-3911, 2016. ,
Matrix metalloproteinases: a review of their structure and role in systemic sclerosis, J Clin Immunol, vol.32, pp.1409-1423, 2012. ,
Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses, Cell Rep, vol.9, pp.1856-70, 2014. ,
Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12-and OX40L-dependent pathway, Cancer Cell, vol.19, pp.333-379, 2011. ,
Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients, J Autoimmun, vol.15, pp.61-67, 2000. ,
Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts, Eur J Immunol, vol.33, pp.2792-800, 2003. ,
Increased serum soluble CD40 levels in patients with systemic sclerosis, J Rheumatol, vol.34, pp.353-361, 2007. ,
High expression of CD40 on skin fibroblasts from patients with systemic sclerosis, Rheumatol Int, vol.28, pp.95-102, 2007. ,
DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility, Arthritis Rheum, vol.64, pp.2338-2383, 2012. ,
Epigenetic mechanisms: an emerging role in pathogenesis and its therapeutic potential in systemic sclerosis, Int J Biochem Cell Biol, vol.67, pp.92-100, 2015. ,
Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers, Ann Rheum Dis, vol.64, pp.481-484, 2005. ,
Capillaroscopic findings and vascular biomarkers in systemic sclerosis: association of low CD40L levels with late scleroderma pattern, Microvasc Res, vol.108, pp.17-21, 2016. ,
Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment, J Rheumatol, vol.44, pp.631-639, 2017. ,
Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis, Ann Rheum Dis, vol.72, pp.1089-98, 2013. ,
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis, Arthritis Rheum, vol.63, pp.1097-105, 2011. ,
A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis, Arthritis Res Ther, vol.14, p.85, 2012. ,
Increased CD226 expression on CD8+ t cells is associated with upregulated cytokine production and endothelial cell injury in patients with systemic sclerosis, J Immunol Baltim Md, vol.195, pp.892-900, 1950. ,
Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, vol.378, pp.158-68, 2018. ,
Scleroderma induced by pembrolizumab: a case series ,
, Mayo Clin Proc, vol.92, pp.1158-63, 2017.
Scleroderma-like skin changes induced by checkpoint inhibitor therapy, J Cutan Pathol, vol.45, pp.615-623, 2018. ,
CTLA-4 can function as a negative regulator of T cell activation, Immunity, vol.1, pp.405-418, 1994. ,
The soluble CTLA-4 receptor and its role in autoimmune diseases: an update, Auto Immun Highlights, vol.1, pp.73-81, 2010. ,
The CTLA-4 and MCP-1 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis, Immunol Invest, vol.42, pp.481-92, 2013. ,
Macrophage involvement in systemic sclerosis: do we need more evidence?, Curr Rheumatol Rep, vol.18, 2016. ,
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma, Oncoimmunology, vol.5, p.1151594, 2016. ,
The PD-1/PD-Ls pathway and autoimmune diseases, Cell Immunol, vol.290, pp.72-81, 2014. ,
Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: association with extent of skin sclerosis, J Dermatol, vol.43, pp.954-961, 2016. ,
Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis, Arthritis Rheumatol, vol.69, pp.1879-90, 2017. ,
Emerging strategies for treatment of systemic sclerosis, J Scleroderma Relat Disord, vol.1, pp.186-93, 2016. ,
Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension, BMC Immunol, vol.12, p.67, 2011. ,
Abatacept: a review in rheumatoid arthritis, Drugs, vol.77, pp.1221-1254, 2017. ,
Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis, Ann Rheum Dis, vol.75, pp.2142-2151, 2016. ,
, , 2018.
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study, Ann Rheum Dis, vol.72, 2013. ,
Abatacept induces clinical improvement in patients with severe systemic sclerosis, Scand J Rheumatol, vol.43, pp.342-347, 2014. ,
Gene expression changes reflect clinical response in a placebocontrolled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis, Arthritis Res Ther, vol.17, p.159, 2015. ,
Safety profile of abatacept in rheumatoid arthritis: a review, Clin Ther, vol.32, 2010. ,